Open AccessIdentification of therapeutic targets and mechanisms of tumorigenesis in non-small cell lung cancer using multiple-microarray analysis
Author(s) -
Dan Zhao,
MU Hai-jun,
Hai Bing Shi,
Hong Xia Bi,
Yun Jiang,
Guo Hua Liu,
Hong Zheng,
Bo Liu
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000022815
Subject(s) - kegg , carcinogenesis , lung cancer , microarray analysis techniques , cyclin dependent kinase 1 , cell cycle , microarray , computational biology , cancer research , gene , cancer , medicine , biology , bioinformatics , gene expression , oncology , genetics , transcriptome
Lung cancer is the most commonly occurring cancer attributed to the leading cause of cancer-related deaths globally. Non-small cell lung cancer (NSCLC) comprises 85% to 90% of lung cancers. The survival rate of patients with advanced stage NSCLC is in months. Moreover, the underlying molecular mechanisms still remain to be understood. We used 2 sets of microarray data in combination with various bioinformatic approaches to identify the differentially expressed genes (DEGs) in NSCLC patients. We identified a total of 419 DEGs using the Limma package. Gene set enrichment analysis demonstrated that “Citrate cycle (TCA cycle),” “RNA degradation,” and “Pyrimidine metabolism” pathways were significantly enriched in the NSCLC samples. Gene Ontology annotations of the 419 DEGs primarily comprised “glycosaminoglycan binding,” “cargo receptor activity,” and “organic acid binding.” Kyoto Encyclopedia of Genes and Genomes analysis revealed that DEGs were enriched in pathways related to “Malaria,” “Cell cycle,” and “IL-17 signaling pathway.” Protein protein interaction network analysis showed that the hub genes constituted of CDK1, CDC20, BUB1, BUB1B, TOP2A, CCNA2, KIF20A, CCNB1, KIF2C, and NUSAP1. Taken together, the identified hub genes and pathways will help understand NSCLC tumorigenesis and develop prognostic markers and therapeutic targets against NSCLC.